A Changing Path in Global Sourcing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Changing Path in Global Sourcing
The European Union's REACH initiative has the potential to affect the flow of chemicals into the pharmaceutical suppy chain.


Pharmaceutical Technology
Volume 3, Issue 32

The sourcing of active pharmaceutical ingredients (APIs) and intermediates is an international affair. Much attention has been focused on using offshore sites for pharmaceutical manufacturing to secure low-cost production. Although this approach certainly remains an important issue, regulatory concerns are dominating the headlines in global sourcing. For 2008, the implementation of the REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals) regulation, a new European Union policy on chemicals and their safe use, looms large.

The terms of REACH

REACH came into force in the EU on June 1, 2007, with the goal of establishing a uniform system for assessing the risk posed by new and existing chemicals (See sidebar, "Basic elements of REACH").


Patricia Van Arnum
REACH requires EU-based manufacturers and EU-based importers doing business, directly or indirectly in Europe, to register chemicals and their uses with the newly created European Chemicals Agency (see sidebar, "REACH and the European Chemicals Agency"). Companies will eventually be required to provide toxicity data for substances produced or imported into the EU in quantities above 1 metric ton per year. Companies will also be required to submit a comprehensive risk assessment, called a chemical safety report, covering the various uses of the materials they register. For approximately 1500–2000 chemical substances, companies will have to go through an authorization process to get permission to continue to use those substances (1).

The aim of REACH is to create a single system for "existing" and "new" substances. Substances are classified as non-phase-in substances (those not produced or marketed prior to the entry into force of REACH) and phase-in substances [substances listed in the European Inventory of Existing Chemical Substances (EINECS) or those that have been manufactured in the EU, but not marketed, in the past 15 years]. Approximately 30,000 phase-in substances (excluding intermediates) are expected to be registered during REACH's 11-year implementation.

Manufacturers and suppliers are facing the first critical phase in REACH implementation. Preregistration is from June 1, 2008, to Dec.1, 2008. To preregister an existing compound, the name of the compound, the Chemical Abstract Service (CAS) number, the EINECS number, the name and address of the registrant, and the tonnage must be reported to the European Chemicals Agency in Helsinki (1).

Compliance with REACHis an important consideration for chemical manufacturers and suppliers, including those that supply the pharmaceutical industry. "The major concern is that many in the industry do not know what the requirements are. The regulations are very complex, and the guidance provided by the EU has done little in the way of making the requirements for companies easier to understand," says Tucker Helmes, senior director of the Visions Department of the Synthetic Organic Chemical Manufacturers Association (SOCMA). SOCMAis the US-based trade association representing custom and batch manufacturers, including contract manufacturers of APIs and intermediates.


REACH and the European Chemicals Agency
"There is also concern about the quality and number of staffers in Helsinki. The European Chemicals Agency is far from fully staffed, and there is concern that it won't be ready in time for preregistration," says Helmes.

Another point for consideration is whether pharmaceutical ingredients are exempt from REACH. The REACH regulation exempts substances used in medicinal products that fall within the scope of Regulation 726/2004 (centralized procedures), Directive 2001/82/EC (veterinary use), and Directive 2001/83/EC (human use). The REACH regulation, however, does not clearly state whether the exemption applies to ingredients before they are incorporated into finished pharmaceutical products. Therefore, there is some uncertainty as to what extent pharmaceutical ingredients (such as APIs, excipients, and intermediates) are subject to REACH. The European Commission plans to review those exemptions in Annexes IVand V of the REACH regulation by June 2008.

Nonisolated intermediates are exempt. On-site isolated intermediates and transported isolated intermediates are subject to lesser registration requirements. Also, substances used for product- and process-oriented research and development may be exempted from registration for certain time periods (1, 2).


Basic elements of the REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals) regulation
"My understanding is that finished pharmaceutical products are exempt from REACH registration. Makers of APIs or intermediates that are sold to US drug manufacturers only should not have an obligation. It would be a worry only for APIs or intermediates sold directly into the EU," says Helmes.

Under REACH, EU-based manufacturers and EU-based importers will need to obtain information on the substances they manufacture or import to assess the risks and to ensure that the risks are properly managed (1). Registration documents the execution of this responsibility. Manufacturers and importers must submit a technical dossier for substances in quantities of 1 metric ton or more and a chemical safety report for substances in quantities of 10 metric tons or more (1). REACH provides transitional periods for registering phase-in substances, provided the substance is preregistered.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here